22
Views
2
CrossRef citations to date
0
Altmetric
Research Article

Effect of N6-Cyclopentyladenosine on Ouabain-Induced Toxicity in Isolated Guinea Pig Atria

, , , , &
Pages 581-583 | Received 12 Mar 2007, Accepted 10 Jul 2007, Published online: 20 Oct 2008
 

ABSTRACT

The effect of N6-cyclopentyladenosine (CPA), an A1-selective adenosine agonist, was studied on ouabain-induced toxicity in spontaneously beating isolated guinea pig atria. CPA (2–16 nM) produced a dose-dependent decrease in the force of contractions (34%–51%) and in the rate of contractions (22%–48%). CPA significantly increased the time of onset of arrhythmia (toxicity) induced by ouabain (1.2 μM) when it was administered 10 min before ouabain was added in organ bath. Ouabain (1.2 μM) alone produced arrhythmia at 7 min and either asystole or standstill at 22 min. CPA (8 nM) increased the time required to produce arrhythmia to 27.5 min and prolonged beating atria to more than 63 min and prevented the occurrence of asystole. These findings indicated that CPA produces direct cardiac action, probably due the inhibition of cardiac Na+ and Ca2+ channels. Moreover, our results suggest that CPA may reduce the membrane conduction through inhibition of ionic channels, which decrease ouabain-induced toxicity.

This work was supported by the Medical School of Tehran University of Medical Sciences; I.R. Iran grant No. 132/9234.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.